Limited-Stage SCLC: Chemoradiotherapy Standards and Scheduling Decisions

This episode, "Limited-Stage SCLC: Chemoradiotherapy Standards and Scheduling Decisions," features the panel detailing the chemotherapy and radiation regimens that define curative-intent treatment today.

This episode centers on the current standard of care for limited-stage small cell lung cancer: concurrent platinum-doublet chemotherapy combined with thoracic radiation, delivered with curative intent. The panel describes a typical regimen of four cycles of platinum plus etoposide, noting that recent data show cisplatin and carboplatin perform comparably, making the two platinum agents largely interchangeable in this setting. Radiation is usually layered in starting with cycle two or three of chemotherapy, allowing time for cytoreduction first, unless a clinical emergency such as superior vena cava syndrome demands radiation sooner. Even with this approach, cure rates without immunotherapy hover around 30%, with median overall survival of two to three years for all comers.

Scheduling choices come next, and the group works through the trade-offs between daily, twice-daily, and sequential chemoradiotherapy. Twice-daily radiation may offer a modest efficacy edge, but it is not always logistically feasible for patients balancing work, caregiving, or travel. Frailer patients, or those less able to tolerate concurrent treatment, may instead receive sequential chemotherapy and radiation, even though outcomes are generally better when the two are delivered together. The panel stresses that these decisions have to be individualized, weighing performance status and life circumstances alongside efficacy data, and made collaboratively with radiation oncology as part of a multidisciplinary team.

The episode closes with a discussion of how treatment success is monitored. Before consolidation immunotherapy became available, clinicians relied on CT scans roughly a month after chemoradiotherapy to confirm response, then continued surveillance scans every few months, watching for eventual disease progression that would prompt second-line therapy. That surveillance-only approach set the stage for the practice-changing data on consolidation therapy discussed in the episodes that follow.

Our next episode, "The ADRIATIC Trial: Consolidation Immunotherapy in Limited-Stage SCLC," examines the trial data that the panel credits with reshaping the standard of care.